We found a significant trend toward an increase in serum iron and a reduction in serum transferrin during the six months of therapy; conversely, liposomal iron supplementation did not significantly change the hemoglobin level, and nor did the use of erythropoiesis-stimulating agents.
← all excerpts
Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
1
—
—